SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

05 May 2023 Evaluate
The revenue for the March 2023 quarter is pegged at Rs. 8488.60 millions, about 10.87% up against Rs. 7656.30 millions recorded during the year-ago period.The Net proft of the company remain more or less same to Rs. 1172.10  millions from Rs. 1348.40 millions ,decline by -13.07%.Operating Profit reported a sharp decline to 1812.80 millions from 2155.70 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 8488.60 7656.30 10.87 34112.70 31406.40 8.62 34112.70 31406.40 8.62
Other Income 367.50 284.20 29.31 1327.50 1397.30 -5.00 1327.50 1397.30 -5.00
PBIDT 1812.80 2155.70 -15.91 8320.30 10306.20 -19.27 8320.30 10306.20 -19.27
Interest 12.10 71.80 -83.15 52.30 91.20 -42.65 52.30 91.20 -42.65
PBDT 1800.70 2083.90 -13.59 8268.00 10215.00 -19.06 8268.00 10215.00 -19.06
Depreciation 321.10 300.90 6.71 1269.50 1209.60 4.95 1269.50 1209.60 4.95
PBT 1479.60 1783.00 -17.02 6998.50 9005.40 -22.29 6998.50 9005.40 -22.29
TAX 307.50 434.60 -29.25 1411.30 1806.80 -21.89 1411.30 1806.80 -21.89
Deferred Tax -84.50 -34.90 142.12 -29.30 95.10 -130.81 -29.30 95.10 -130.81
PAT 1172.10 1348.40 -13.07 5587.20 7198.60 -22.38 5587.20 7198.60 -22.38
Equity 252.70 171.70 47.18 252.70 171.70 47.18 252.70 171.70 47.18
PBIDTM(%) 21.36 28.16 -24.15 24.39 32.82 -25.67 24.39 32.82 -25.67

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×